Your browser doesn't support javascript.
loading
Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.
Schramm, Elizabeth C; Roumenina, Lubka T; Rybkine, Tania; Chauvet, Sophie; Vieira-Martins, Paula; Hue, Christophe; Maga, Tara; Valoti, Elisabetta; Wilson, Valerie; Jokiranta, Sakari; Smith, Richard J H; Noris, Marina; Goodship, Tim; Atkinson, John P; Fremeaux-Bacchi, Veronique.
Afiliación
  • Schramm EC; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO;
  • Roumenina LT; INSERM UMRS 1138, Cordeliers Research Center, Paris, France; Université Paris Descartes Sorbonne Paris-Cité, Paris, France; Université Pierre et Marie Curie, Paris, France;
  • Rybkine T; INSERM UMRS 1138, Cordeliers Research Center, Paris, France; Université Paris Descartes Sorbonne Paris-Cité, Paris, France; Université Pierre et Marie Curie, Paris, France;
  • Chauvet S; INSERM UMRS 1138, Cordeliers Research Center, Paris, France; Université Paris Descartes Sorbonne Paris-Cité, Paris, France; Université Pierre et Marie Curie, Paris, France;
  • Vieira-Martins P; INSERM UMRS 1138, Cordeliers Research Center, Paris, France;
  • Hue C; INSERM UMRS 1138, Cordeliers Research Center, Paris, France; Université Paris Descartes Sorbonne Paris-Cité, Paris, France; Université Pierre et Marie Curie, Paris, France;
  • Maga T; Molecular Otolaryngology and Renal Research Laboratories, and Rare Renal Disease Clinic, Departments of Pediatrics and Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA;
  • Valoti E; Laboratory of Immunology and Genetics of Transplantation and Rare Diseases, Mario Negri Institute for Pharmacological Research, Ranica Bergamo, Italy;
  • Wilson V; Northern Molecular Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom;
  • Jokiranta S; Department of Bacteriology and Immunology, Medicum, and Research Programs Unit, Immunobiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;
  • Smith RJ; Molecular Otolaryngology and Renal Research Laboratories, and Rare Renal Disease Clinic, Departments of Pediatrics and Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA;
  • Noris M; Laboratory of Immunology and Genetics of Transplantation and Rare Diseases, Mario Negri Institute for Pharmacological Research, Ranica Bergamo, Italy;
  • Goodship T; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; and.
  • Atkinson JP; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO;
  • Fremeaux-Bacchi V; INSERM UMRS 1138, Cordeliers Research Center, Paris, France; Université Paris Descartes Sorbonne Paris-Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Assistance Publique-Hôpitaux de Paris, Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, Paris, France.
Blood ; 125(15): 2359-69, 2015 Apr 09.
Article en En | MEDLINE | ID: mdl-25608561
ABSTRACT
The pathogenesis of atypical hemolytic uremic syndrome (aHUS) is strongly linked to dysregulation of the alternative pathway of the complement system. Mutations in complement genes have been identified in about two-thirds of cases, with 5% to 15% being in C3. In this study, 23 aHUS-associated genetic changes in C3 were characterized relative to their interaction with the control proteins factor H (FH), membrane cofactor protein (MCP; CD46), and complement receptor 1 (CR1; CD35). In surface plasmon resonance experiments, 17 mutant recombinant proteins demonstrated a defect in binding to FH and/or MCP, whereas 2 demonstrated reduced binding to CR1. In the majority of cases, decreased binding affinity translated to a decrease in proteolytic inactivation (known as cofactor activity) of C3b via FH and MCP. These results were used to map the putative binding regions of C3b involved in the interaction with MCP and CR1 and interrogated relative to known FH binding sites. Seventy-six percent of patients with C3 mutations had low C3 levels that correlated with disease severity. This study expands our knowledge of the functional consequences of aHUS-associated C3 mutations relative to the interaction of C3 with complement regulatory proteins mediating cofactor activity.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complemento C3 / Mapas de Interacción de Proteínas / Síndrome Hemolítico Urémico Atípico Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complemento C3 / Mapas de Interacción de Proteínas / Síndrome Hemolítico Urémico Atípico Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article